# C_2009145EN.01002001.xml

| 25.6.2009 | EN | Official Journal of the European Union | C 145/20 |
| --- | --- | --- | --- |

25.6.2009

EN

Official Journal of the European Union

C 145/20

---

Prior notification of a concentration

(Case COMP/M.5530 — GlaxoSmithKline/Stiefel Laboratories)

(Text with EEA relevance)

2009/C 145/13

| 1. | On 15 June 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking GlaxoSmithKline plc (‘GSK’, UK) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Stiefel Laboratories Inc. (‘Stiefel Laboratories’, USA) by way of a corporate merger of a subsidiary of GSK and Stiefel Laboratories. |
| --- | --- |

1.

On 15 June 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking GlaxoSmithKline plc (‘GSK’, UK) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Stiefel Laboratories Inc. (‘Stiefel Laboratories’, USA) by way of a corporate merger of a subsidiary of GSK and Stiefel Laboratories.

1

| 2. | The business activities of the undertakings concerned are:






  — | for undertaking GSK: discovery, development, manufacture and commercialization of pharmaceutical products and consumer health related products, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for undertaking GSK: discovery, development, manufacture and commercialization of pharmaceutical products and consumer health related products,

| — | for undertaking Stiefel Laboratories: discovery, development, manufacture and commercialization of pharmaceutical products, in particular dermatological pharmaceutical and skin care products. |
| --- | --- |

—

for undertaking Stiefel Laboratories: discovery, development, manufacture and commercialization of pharmaceutical products, in particular dermatological pharmaceutical and skin care products.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 2 2964301 or 2967244) or by post, under reference number COMP/M.5530 — GlaxoSmithKline/Stiefel Laboratories, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 2 2964301 or 2967244) or by post, under reference number COMP/M.5530 — GlaxoSmithKline/Stiefel Laboratories, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---